• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    5/20/25 4:15:10 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email
    8-K
    false 0000867840 0000867840 2025-05-14 2025-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) May 14, 2025

     

    PRECISION OPTICS CORPORATION, INC.

    (Exact name of registrant as specified in its charter)

     

    Massachusetts   001-10647   04-2795294
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)
             

     

    22 East Broadway
    Gardner
    , Massachusetts
      01440
    (Address of principal executive offices)   (Zip Code)

     

    (Registrant’s telephone number, including area code) (978) 630-1800

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.01 per share   POCI   The Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

         

     

       
     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    As previously disclosed in Precision Optics Corporation, Inc.’s (the “Company”) Form 10-Q for the period ended March 31, 2025, as filed with the Securities and Exchange Commission on May 15, 2025, on May 14, 2025, the Company entered into a Lease Agreement (the “Lease”) with 400 Southborough, LLC (the “Landlord”), pursuant to which the Company will lease approximately 8,750 square feet of commercial space located at 500 Southborough Drive, City of South Portland, County of Cumberland, Maine (the “Premises”). The Lease provides for an initial term commencing on the date the Landlord obtains a certificate of occupancy for the Premises and all Landlord work is substantially complete and expiring on the last day of the calendar month during which the eighth anniversary of the commencement date occurs. The commencement date is anticipated to be August 1, 2025, subject to Landlord’s review of floor plans and associated estimated construction timeframe.

     

    The Lease provides the Company with two options to extend the term for additional five-year periods, exercisable with at least nine months’ prior written notice. Base rent for the initial term is abated for the first five months following the commencement date, after which annual base rent payable is $131,250 (or $10,937.50 per month), with annual increases of 3%. Base rent for any extension term will be as agreed by the parties or, if not agreed, at 95% of the then-current fair market base rental rate for similar space in South Portland, as determined by appraisal, with annual increases of 3% during each extension term.

     

    In addition to base rent, the Company is responsible for its proportionate share (19.34%) of Operating Expenses, as defined in the Lease. The Lease is structured as a triple net lease. The Company is entitled to a tenant improvement allowance of $25 per rentable square foot for fit-up costs and $0.15 per rentable square foot for architectural costs, to be disbursed as costs are incurred. The Landlord is responsible for completing certain improvements to the Premises prior to occupancy, including interior wall construction, loading area, and separate utility metering. If delivery of the Premises is delayed beyond September 1, 2025, for reasons within the Landlord’s control, the Company is entitled to one day of abated rent for each day of delay. The Lease contains customary provisions regarding use, maintenance, alterations, assignment and subletting (including certain permitted transfers without Landlord consent), insurance, indemnification, waiver of subrogation, casualty, eminent domain, estoppel certificates, subordination, quiet enjoyment, and remedies upon default.

     

    The foregoing description of the Lease does not purport to be a complete statement of the parties’ rights and obligations and is qualified in its entirety by reference to the full text of the Lease, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Exhibit Description
    10.1   Lease, dated May 14, 2025, by and between 400 Southborough, LLC and Precision Optics Corporation, Inc.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

     

     3 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PRECISION OPTICS CORPORATION, INC.
       
       
    Dated: May 20, 2025 By:  /s/ Joseph N. Forkey
      Name: Joseph N. Forkey
    Title: President

     

     

     

     

     

     

     

     

     

     

     4 

     

    Get the next $POCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woodward Peter H exercised 30,000 shares at a strike of $2.19 and covered exercise/tax liability with 14,536 shares (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      5/20/25 4:15:06 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Pellegrino Joseph P Jr

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      3/21/25 4:17:04 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman was granted 20,000 shares, increasing direct ownership by 16% to 142,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      3/21/25 4:15:13 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precision Optics Reports Third Quarter Fiscal Year 2025 Financial Results

      GARDNER, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its third quarter fiscal year 2025 for the period ended March 31, 2025. Q3 2025 Financial Highlights (3 Months Ended March 31, 2025): Revenue was $4.2 million compared to $5.2 million in the same quarter of the previous fiscal year and compared to $4.5 million in the most recent sequential quarter.Production revenue was $3.3 million compared to $3.0 million in the same quarter of the previous fiscal year and compared to $

      5/15/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

      GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). Dr. Joe Forkey, Chief Executive Officer of Precision Optics, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapCl

      4/21/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

      GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

      3/4/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

      GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

      7/8/24 9:00:00 AM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

      SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      11/13/24 5:53:45 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Precision Optics Corporation Inc.

      SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      5/17/24 5:03:18 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:31 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:30 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:33 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Financials

    Live finance-specific insights

    See more
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Second Quarter of Fiscal Year 2025 Conference Call for February 13, 2025

      GARDNER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2025 financial results on Thursday, February 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, February 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, February 13, 2025, at 5:00 p.m. ET. Call-in Information: Inter

      2/11/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Schedules First Quarter of Fiscal Year 2025 Conference Call for November 14, 2024

      GARDNER, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2025 financial results on Thursday, November 14, 2024, at 5:00pm ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 14, 2024, followed by the conference call. Conference Call Details Date and Time: Thursday, November 14, 2024, at 5:00pm ET Call-in Information: Interested pa

      11/11/24 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    SEC Filings

    See more
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/20/25 4:15:10 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/19/25 4:30:09 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Precision Optics Corporation Inc.

      10-Q - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/15/25 4:15:46 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care